Title. Author(s)SATO, Gihei; HIRATO, Katsushichi. CitationJapanese Journal of Veterinary Research, 2(4): Issue Date DOI.

Size: px
Start display at page:

Download "Title. Author(s)SATO, Gihei; HIRATO, Katsushichi. CitationJapanese Journal of Veterinary Research, 2(4): Issue Date DOI."

Transcription

1 Title SOME OBSERVATIONS ON THE NON-SPECIFICALLY ENHANCED R INTRAPERITONEAL INFECTION WITH SALMONELLA ABORTUS-EQ Authr(s)SATO, Gihei; HIRATO, Katsushichi CitatinJapanese Jurnal f Veterinary Research, 2(4): Issue Date DOI /jjvr Dc URL Type bulletin File Infrmatin KJ pdf Instructins fr use Hkkaid University Cllectin f Schlarly and Aca

2 SOME OBSERVATIONS ON THE NON.. SPECIFICALLY ENHANCED RESISTANCE OF MICE AGAINST INTRAPERITONEAL INFECTION WITH SALMONELLA ABOR:L ' US-EQUI Gihei SATO* and Katsushichi HIRATO Labratry f Veterinary Hygiene and Micrbilgy, Faculty f Veterinary Jtl edicine, Hkkaid University, Sappr, Japan (Received fr Publicatin, Octber 7, 1954) Muse-prtectin test is very practical fr a~saying the ptency f varius vaccines. In this test, administratins f the immunizing injectins and f the challenge dses are ften made by the intraperitneal rute. Hwever, the nn-specifically enhanced resistance f mice that fllws the intraperitneal injectin f varius substances has been bserved by many wrkers. This phenmenn may be an imprtant surce f errrs in all muse-prtectin tests in which the challenge dse is injected by the intraperitneal rute. FEL.IX pinted ut that many wrkers engaged in experiments n typhid immunity use the faulty methd f injecting bth immunizing and challenge dses by the intraperitneal rute. The present authrs have studied n the mice-prtectin tests f the killed vaccine f S. abrtus-equi. In a previus paper, HIRATO et al. recgnized the high ptency f this vaccine in the case f injecting bth the immunizing and the challenge dse by intraperitneal rute. Hwever, it was left as an unslved prblem whether the nn-specific prtective mechanisms wuld play sme part in this prtectin test, and the authrs stated that sme additnal experiments are needed fr the establishment f this pint. ORSKOV and K~UFFMANN, PHILIPSON and 0RSKOV examined in detail the degree and duratin f this kind f nn-specific resistance. Frm thse studies, it is learned that ne intraperitneal dse f a vaccine f sme kinds f bacteria induces in mice a high degree f immunity t intraperitneal challenge with the ther kinds f bacteria and that the repeated injectins f the vaccine induce a lnger duratin f the same type f immunity. Frm these well established facts, it wuld seem tbat the same thing might interfere with the results f the muse-prtectin test f 'equine paratyphid vaccine. The present study was carried ut t * Present addre3s: Labratry f Epiztilgy in this faculty Jap. J. Vet. Res., Vl. 2, N.4, 1954

3 178 SATO, G. AND K. HIRATO ascertain the nn-specific rise f resistance in case f assaying the prtective value f this vaccine. MATERIALS AND METHODS Bacterial Strain: The strain f S. abrtus-equi used fr the preparat.in f vaccine and the test culture was a pretty fresh ne. A relatively ld stck culture f Escherichia cli var. cmmunir was used fr preparatin f a heterlgus vaccine. It had n cmmn antigenic cnstituents with S. abrtus-equi. Vaccine Preparatin: Heat-kiIIed vaccine was prepared frm saline suspensin f plain nutrient agar culture by heating at 60 C fr 40,..,...50 minutes. Chrme-vaccine Bacterial suspensin (1% frml saline) was mixed with equal vlume f 0.4% alum chrmate slutin. After having std fr 2 days at rm temperature, this suspensin was centrifuged and the sediment was washed tw times in nrmal saline. Muse-test: The same strain f white muse was used thrughut as described in previus papers n the muse-prtectin test f ~quine paratyphid vaccine. They were f female sex in almst all experiments, and weighed abut 15 g at the time f infectin. Mice were immunized by intraperitneal rute, with 0.5 ml saline suspensin cntaining respectively each vaccine dse f hmlgus r heterlgus bacteria and the challenge dse f S. abrtus-equi was given in the same manner after varius intervals. In rder t avid any fluctuatin f bacterial number f the challenge dse, the infectin was made simultaneusly against all grups f mice having different intervals after tbe immunizing injectins. Heart bld f mice which died was cultured t ascertain whether death had ccurred as a result f infectin. In the latter part f the experiments, bacilli in tail bld f infected mice were examined by cultural methd. Tw drps f bld were cultured n ENDO agar and a lpful f bld was enriched with brth cntaining sapnine and sdium citrate. Other detailed descriptins f experimental methds will be given in the next chapter. EXPERIMENTAL RESULTS 1. The Nn-specific Resistance f Mice t Fatal Infectin with a Large Dse f S. C!hrlus-equi. In the muse-prtectin test f equine paratyphid vaccine, the challenge dse is given after an interval f abut 10 days with a sufficient dse usually t cause septicaemic death. Firstly t investigate the effect f nn-specifically increased intraperitneal resistance, the authrs used tw kinds f killed vaccine. Each.grup f 3,...,4 mice was injected intraperitneally with 0.2 mg f heat-killed bacilli f abrtin r cli at perids ranging frm 1 t 14 days befre infectin as indicated in table 1. Intraperitneal challenge dse f 0.15 mg f abrtin bacilli was given t each immunized grup simultaneusly..,.

4 On the Nn-Specifically Enhanced Resistance 179 TABLE. I. Surm'val Rate f Mice Immunized with Heterlgus r Hmlgus Vaccines within 30 Days after Fatal Infectin with S. abrtus-equi GROUPS IMMUNIZED INTERVALS BETWEEN VACCINATION AND INFECTION WITH HEAT-KILLED BACILLI OF days S. abrtus-equi 0/4 E. cli 2/4 Cntrls Vaccine dse: 0.2 mg i. p. Challenge ds'e: 0.15 mg i. p. 1/4 0/4 1/4 4/4 3/3 3/3 0/4 0/4 0/3 0/3 0/4 A glance at table 1 shws that a certain prtective resistance appeared in a mice grup infected at an interval f 1 day after heterlgus vaccinatin. In case f hmlgus vaccinatin, the mice grup infected at a 2- and 4-day interval indicated lw survival rate. This result seems t indicate that mice acquire sme resistance against fatal infectin when they are immunized with heterlgus r hmlgus vaccine and these nn-specific intraperitneal resistances appear at an earlier perid in cmparisn with specific immunity, In the latter experiment, a'larger dse f vaccine was used than that in the previus experiment, and infected mice were bserved clinically fr 30 days after infectin. This was dne because, in natural cnditin, mice infected with al~rtin TABLE 2. Resistance f )l,iice at Varius Intervals after Intraperitneal Treatment t Infectin with a Large Challenge Dse f S. abrtus-equi INTERVALS BETWEEN V ACCINATION AND INFECTION 1/ Cntrls SORVIV AL DAYS OF MICE IMMUNIZED WITH 3, 4, 4, 5, 5. 4, 4, 5. S, S, S. 5,5, 5, 5. 6, 6, 6, s. 5, 6, 6, 7. 1, 4, 4, 5. 4, 4, 5, 7, -x. 4, 5, 6, s. ** 4, 5, S, S. 1, 5, 6, 8, Vaccine dse: 0,5 mg i. p. * This grup was given 2 dses f vaccine (0,2, 0.3) with a 7-day interval. *-X. This grup was jnjected with 2 dses f vaccine (0.5, 0.5) with a 7-day interval. Challenge dse: 0.15 mg i. p. S: Survived and healthy fr 30 days after infectin. s: Survived but suffered frm septicaemia.

5 180 SATO, G. AND K. HIRATO bacilli regularly get septicaemia, but they d nt always die. Therefre by bserving the survival rate nly, ne is apt nt t learn whether they are perfectly prtected frm septicaemia r whether they escaped frm the danger f septicaemic death. Septicaemic mice shw clinical signs such as hair rughening, arched back r lss f appetite and are easily discriminated frm healthy niice. The data in table 2 seem t establish that 0.5 mg f heterlgus vaccine scarcely prduced nn-specific resistance. Hwever, it shuld be nticed that half the number f mice survived in a grup which were immunized with a dse f 1 mg cli vaccine and infected 10 days later. Further, these survived mice did nt suffer frm bth the primary and secndary septicaemia similarly t mice hmlgusly vaccinated. Frm the abve bservatins, it may be stated that mice immunized with killed vaccine f abrtin r cli bacilli resist slightly against fatal infectin with a large dse sllch as 0.15 mg f abrtin bacilli at the early perid after vaccinatin, but 1 mg f heter-vaccine gives a cmplete prtective pwer t sme f the mice n the 10 th day after vaccinatin. 2. Effect f the Nn-specific Resistance f Mice n the Destructin f Intraperitneally Injected Bacilli The previus experiments seem t shw that mst f the mice treated specifically r nn-specifically d nt strngly demnstrate nn-specific resistance t fatal infectin with a large dse f abrtin bacilli. Hwever, it is prbable that severe infectin caused by a large challenge dse may cver the feeble rise in nn-specific resistance, s hw t detect such a feeble resistance shuld be cnsidered. Accrding t the previus investigatins, abrtin bacilli injected with a prper dse int the peritneal cavity enter int the bld stream rapidly, but the immunized mice tend t inhibit this invasin by destructin f injected bacilli. Therefre, if the number f bacilli in bld stream is decided by cultural methd at different intervals fllwing infectin, the degree f resistance f mice may be bserved indirectly. Infectin with 0.01 mg f abrtin bacilli is able t prduce a bacteremia fr 1 week almst at the rate f 100%, but des nt kill the mice rapidly. As shwn in table 3, each grup f 4 mice was injected with 0.01 mg f abrtin bacilli and tail blds f mice were cultured during the time frm half an hur t the 7th day after infectin. Then the percentage f the psitive cultures was calculated as fllws: Ttal nt!-mber f psitive cultures in each grup 100 Ttal number f bld cultures in each grup x (In the case f mice which died within 1 week after infectin in the further experiments, the results f bld cultures were estimated t be psitive frm the date f death t the 7th day). Thus the lwer the percentage f psitive cllltures the larger becmes resistance f the grup f mice against infectin.

6 On the Nn-Specifically Enhanced Resistance 181 TABLE 3. Shwing the Result f Tail Bld Culture at Varius Times after Inculatin f S. abrtus-equi int H mlgusly and Heterlgu8ly Vaccinated M'ice. MICE IMMUNIZED INTERVALS RESULTS OF BLOOD CULTURES. BETWEEN WITH HEAT-KILLED VACCINATION BACILLI OF AND INFECTION 1/ ~~s days S. abrtus-equi 0.2 mg E. cli 0.2, 0.2 S. abrtus-equi 0.2 E. cli 0.2 Cntrls 11 days J () 0 I ~ ~ ~ ~ 1 day 1 day 1 day I It ~ ~ ~ l () =11 () 0 f It () H = 1 H f H 0 00 I D () It It It ~.. : : () 0 I * : : : f () 0 = () = It = 1 It = H () Challenge dse: 0.01 mg i. p. : negative culture ( ): psitive in enrichment culture : 1-50 clnies : clnies 1: ver 100 D: death Calculatin f Percentage f Psitive Cultures: Ttal Number f Psitive Cultures in each Grup X 100 Ttal Number f Bld Cultures in each Grup PERCENTAGE OF POSITIVE CuLTURES 6/40 x 100 = 15% 40% 82.5;:;; 80'}{' 100% It may be seen frm table 3, that a dse f 0.2 rug f heter- r hm-vaccine prduced slight nn-specific resistance, and the increase f the dse t 0.4 rug f heter-vaccine develped an appreciable nn-specific resistance against S. abrtus ('qui. These results seem t indicate that the nn-sr;ecific intraperitneal resistance is induced n the 1st day after vaccinatin depending n the dse f heter-vaccine. By means f the abve assaying cnceptin, the results f the fllwing experiments have been simplified as is shwn in table 4.

7 182 SATO, G. AND K. HIRATO GROUPS IMMUNIZED WITH HEAT-KILLED BACILLI OF TABLE 4. Nn-specific Resistance f Mice which were Tested at Varius Intervals between Vaccinatin and Challenge Dse PERCENTAGE OF POSITIVE BLOOD CULTURES (Intervals between Vaccinatin and Infectin) 7 hrs days ----_ '- S. abrtus-equi E. cli Cntrls 100% 45.4% 15.1% 96.9% 100% 100% 78.7% 75.7% 100%* 42.7%** 100% Vaccine dse: 0.2 mg i. p. * This grup was injected with 2 dses f vaccine (0.1, 0.1) with a 7-day interval. ** This grup was injected with 3 dses f vaccine (0.2, 0.2, 02) with 2-day intervals. Challenge dse: 0.01 mg f S. abrtus-equi i. p. Three mice were used in each grup. Percentages f psitive cultures in table 4 indicate that 0.2 mg f killed abrtin bacilli induced a certain resistance f nn -specific type n the 3rd day after vaccinatin, but the same dse f heter-vaccine culd hardly prduce it at any interval. On the ther hand, 0.6 mg f heter-vaccine induced the nn-specific resistance n the 10th day after treatment. Results btained frm tables 3 and 4 shw that the nn-specific resistance caused by a small dse f 0.2 mg f heterr hm-vaccine was slightly demnstrated n the 1st day after treatment and increased resistance was develped with a large dse f 0.4 mg f heter-vaccine at the same interval. Mrever, a cnsiderably larger dse f heter-vaccine induced the nn-specific resistance n the 10th day after treatment. Intraperitneal treatment with hm-vaccine tends t induce pwerfully the nn-specific rise in resistance (prmunity) in earlier pint f time than the specific types f immunity. Table 5 indicates nn -specific resistance caused by varius vaccines f heterbacteria at different intervals after treatment. As will be nted frm this table, heat-killed vaccine f cli did nt induce the nn-specific resistance 4 hurs after treatment, but it sustained the nn-specific resistance frm the first t the 10th day after treatment. Hithert, repeated injectins f large vaccine dses were made. Hwever, it is very likely that difference f degree between the nn-specific resistance enhanced by the repeated vaccinatin and the same resistance induced by a single dse may be prduced. Therefre, in rder t bserve the exact effect f large vaccine dse n the rise f nn-specific resistance, it is necessary t emply a single injectin. In rder t avid the lss f mice with a single injectin f large vaccine dse, the killed bacilli shuld be detxified. I t is well established by Kji ANDO et al. that the txicity f the killed bacilli is evidently decreased by treatment with alum chrmate. A.ccrdingly, frmlized cli bacilli were treated with 0.4% alum chrmate slutin fr the decrease f the txicity. As indicated in table 5,

8 On the Nn-Specifically Enhanced Res'istance 183 chrme-vaccine injected repeatedly seems t be as effective n the inductin f nn-specific resistance as heat-killed vaccine, but frmlized vaccine is less effective. TABLE 5. Percentage f Psitive Bld C1tltures f Mice Inculated with S. abrtus-equi at Different IntM'vals after V'accinat'in with a Large Dse f Vm'i'us Va;ccines VACCINE Heat-killed Bacilli f S. abrtu,s-equi Frml Vaccine f E. cli Chrme-Vaccine f E. cli Heat-killed Bacilli f E. cn Cntrls DOSE 0.2, 0 2, 02 mg 0.2, INTERVALS BETWEEN LAST VACCINATION AND INFECTION 10 days hrs. PERCENTAGE OF POSITIVE CULTURES 4.5% 70.4~;;; 43.1% 43.1% 47.7% 50.0% 84.1% 97.7'}{, 79.5.% Interval f repeated vaccinatin is 2-days. Challenge dse: 0.01 mg i. p. Fur mice were used in each grup. It may be seen frm table 6 that 1 mg f chrme-vaccine injected at a time gives appreciably higher resistance t the mice than is fund in the mice grup which was given a dse f 0.2 mg. Mrever, as in table 7, in the case f single injectin f 1 rng f cli chrme-vaccine, pwerful nn-specific resistance was bserved even 3 weeks after vaccinatin. (Hwever, the bdy weight f the mice used in this experiment was larger than that in the frmer experiments, s the animals might be much mre resistant'. TABLE 6. DUratin f Nn-specific Resistance f llfice Vacc1,nated uith Single Small 0,' Large Dse f Chrme-vaccine. VACCINE Heat-killed Bacilli f S. abrtus-equi Chrme-vaccine f E. cli Cntrls DOSE (mg) PERCENTAGE OF POSITIVE BLOOD CULTURES (Intervals between Vaccinatin and Infectin) days 38.7r;6 932.% 95.5'} {' 88.7'}'; 100.0'}'; 48.5'}'; 63.6% 43.2% 59.1% 90.9'}''; Challenge dse: 0.01 mg f S. abrtus-equi i. p. Fur mice were used in each grup.

9 184 SATO, G. AND K. HIRATO TABLE 7. Lng Duratin f Nn~specific Resistance f Mice Vaccinated with a Large Dse f Chrme~vaccine VACCINE Heat-killed Bacilli f S. abrtus-equi Chrme vaccine f E. cli Cntrls DOSE (mg) PERCENTAGE OF POSITIVE BLOOD CULTURES (Intervals between Vaccinatin and Infectin) % 6.8% 2.3% 90,9% Challenge dse: 0.01 mg f S. abrtus-equi i. p. Fur mice were used in each grup. Als ther kinds f heter-vaccine besides cli were used t bserve the nnspecific rise in resistance against abrtin bacilli. As shwn in table 8 mice treated with a large dse f different vaccines nn-specifically have been fund t prvide different degrees f resistance. TABLE 8. Nn-specific Resistance Prduced by VaccinaUn f Varius Kinds f Bacteria MICE IMMUNIZED INTERVALS BETWEEN PERCENTAGE OF WITH HEAT-KILLED V ACCINATION AND POSITIVE BLOOD BACILLI OF INFECTION CULTURES S. abrtus-equ,i 5 days 9.1% Staphylcccus aureus 47.7% S. senftenberg 69.7% E. cli 52.3% Cntrls 86.4% Vaccine dse: Three dses (0.25, 0'.25, 0.25) were injected at 2-day intervals. Challenge dse: 0.01 mg f S. abrtu8-equi i. p. Mice injected with killed abrtin bacilli shwed nn-specific resistance t hmlgus infectin n the 3rd day after vaccinatin, and als mice injected with a large dse f cli vaccine prduced a cnsiderably pwerful nn-specific resistance t infectin with abrtin bacilli 10 days after treatment. A single dse f cli chrme-vaccine, such as 1 mg, induced a surprising resistance t infectin fr 3 weeks under certain cnditins. Nn-specific resistance n the 1st day after vaccinatin seemed t be very slight and transient; several hurs after treatment it was nt bservable. Hwever, nn-specific resistance induced by heterlgus bacteria is weaker cmpared with the resistance develped by specific vaccinatin. 'j CONSIDERATION Accrding t 0RSKOV and KAUFF!\fANN, the nn~specific resistance is..

10 On the Nn-Specifically Enhanced Resistance 185 develped with great rapidity after vaccinatin and it fades befre the appearance f specific immunity. Thus this rapidly prduced nnspecific resistance was demnstrable during a shrt time, and they called it prnlunity. On the ther hand, PIIILIl)SO~ fund that the resistance enhanced by means f repeated injectins appears mre rapidly and is f jnger duratin than prmunity. These wrkers reprted that the nn-specific resistance shws the highest degree in the case f injecting bth the immunizing and challenge dse by the intraperitneal rute. The present experiments were designed t determine whether r nt the nn-specifically enhanced intraperitneal resistance has effect n the muse-prtectin test f equine paratyphid vaccine. Accrding t the results btained frm the abve experiments, in the case f specific immunizatin, a nn-specifically enhanced resistance against infectin with abrtin bacilli develped mre rapidly than specific resistance. Als in the nn-specific immunizatin the same resistance appeared at an early perid similar t specific hnmunizatin. Even if this kind f resistance which is bserved at an early tinle may be prduced in muse-prtectin test f the equine paratyphid vaccine, it des nt practically disturb the test. Therefre, it shuld be examined whether the nn-specific resistance which appeared frm early perid is cntinued fr a lng time r nt. This kind f resistance in nn-specific immunizatin is prduced strngly by a large inlmunizing dse and it seems t last in a cnstant degree frm beginning t the 10th day, even if it is slighter than the resistance in the specific immunizatin. Under certain cnditins, a single injectin f 1 mg f heterlgus chrme-vaccine demnstrated a cnsiderably pwerful resistance t infectin with abrtin bacil1i fr 3 weeks, thugh a sluw disslutin f the bacilli might be caused by treatment with alum chrmate slutin. (It is believed that the decrease f txicity f the killed bacilli treated with alum chrmate slutin is due t a slw disslutin f their substances in the tissue). Therefre, it is presunled that nl0usa-prtectin test which is perfrmed by emplying a large dse f equine paratyphid vaccine may be influenced by the nn-specifically enhanced intraperitneal resistance. Accrding t 0H.RKOV and KAUFF:\IAN;-';, and PffILlPRON, regarding the relatin f vaccine dse t the nn-specific resistance, it was rendered clear that the degree r the duratin f this resistance is prprtinal

11 186 SATO, G. AND K. HIRATO t the immunizing dse t sme extent. Als the present authrs btained similar results. Hwever, decrease f resistance bserved at a very early time after vaccinatin seems t be due t a txic effect f a large vaccine dse, as Pnu,u'sN stated in his reprt. Tpe present authrs detected the feeble nn-specific resistance by culturing the tail bld f mice after infectin. PHILIPSON reprted that the destructin f intravenusly r intraperitneally injected living bacilli is mre rapid in nn-specifically immunized mice than in the cntrls. 0RSKOV demnstrated the increased phagcytsis in the peritneal cavity f mice immunized nn-specifical1y. Therefre, the bld culture methd emplyed by the present authrs seems t be apprpriate fr bservatin f the nn-specific resistance. Als ther kinds f bacteria than cli, such as staphylccci r S. senftenberg, slightly induced nn-specific resistance t infectin with S. abrtus-equi 5 days after immunizatin. This result suggests that the resistance enhanced by cli vaccine must be whlly nn-specific. As indicated in table 4, prmunity in specific immunizatin is mre pwerful than in nn-specific immunizatin n the 3rd day after vaccinatin. Frm this result it may be stated that prm unity bserved in muse-prtectin test f equine paratyphid vaccine is relatively specific. As t this pint, 0H.SKOV and KAUFF,IA~N already indicated that the prmunity which appeared in muse-prtectin test f typhid vaccine was nt alway3 f cmplete nn-specificity. Cnsequently, it is reasnable t cnsider that nn-specifically enhanced intraperitneal resistance may have interfered with the authrs' previus experiment n the muse-prtectin test f equine paratyphid vaccine, which was perfrmed by injecting bth immunizing and challenge dse by intraperitneal rute. In rder t avid these cnfusins in case f muse-prtectin test f equine paratyphid vaccine, injectin f vaccine shuld be made by anther rute. Kiyshi ANDO et al. reprted that mice injected subcutaneusly with killed vaccine f a variant strain f S. typh'imurium were rendered slightly resistant t intraperitneal infectin with abrtin bacilli n the 10th day after vaccinatin. Nevertheless, frm the results btained by many wrkers, it is clear that subcutaneus vaccinatin induees nly slightly a nnspecific resistance against intraperitneal infectin with hmlgus r heterlgus bacilli, r did nt at all. Therefre, when the vaccine dse is very large, it is better t emply subcutaneus injectin than intraperitneal. Hwever, accrding t previus experiment f the present

12 On the Nn-Specifically Enhanced Resistance 187 authrs, subcutaneus treatment did nt always give prtective pwer t mice. Thus hw t immunize mice mst effectively is an imprtant prblem fr further investigatin. Mice immunized intra peritneally with killed vaccine f heterlgus bacteria shw an enhanced resistance t an intraperitneal infectin with S. abrtus-equi 1 r 2 days after vaccinatin and sustain it fr a perid extending t 10 days. This nn-specifically enhanced resistance is inferir t the resistance bserved in specific immunizatin. Hwever, in case f injecting a large dse f heterlgus vaccine, nnspecific rise in resistance smetimes becmes cnsiderably high and lasts fr 3 weeks. REFERENCES 1) ANDO, Kiyshi, Y.OCHI & S. SUDO (1934): Saikingaku-Zasshi, N. 464,51 (Japane3e). 2) AN DO, Kji, H. SHIMOJO & 1. TADOKORO (1952): Jap: J. Exp. Med., 22, ) FELIX, A. (1951): J. Hyg., 49, ) HIRATO, K., G. SATO, T. ONO & K. SHIMIZU (1953): Vet. Res., 1, 29 (Japanese with English abstract). 5) PHILIPSON, J. (1937): Acta. Path. Micrbil. Scand., Supp!., 32, 1. 6) 0RSKOV, J. & F. KAUFFMANN (1936): Z. Hyg. u. Infektkr., 119, 65. 7) 0RSKOV, J. (1940): Z. Immun.-Frsch., 98, 359.

STUDIES WITH HUMAN INFLUENZA VIRUS CULTIVATED IN ARTIFICIAL MEDIUM

STUDIES WITH HUMAN INFLUENZA VIRUS CULTIVATED IN ARTIFICIAL MEDIUM Published Online: 1 June, 1936 Supp Inf: http://di.rg/1.184/jem.63.6.83 Dwnladed frm jem.rupress.rg n August 13, 218 STUDIES WITH HUMAN INFLUENZA VIRUS CULTIVATED IN ARTIFICIAL MEDIUM BY T. P. MAGILL,

More information

The estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by

The estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by ESTIMATION PROCEDURES USED TO PRODUCE WEEKLY FLU STATISTICS FROM THE HEALTH INTERVIEW SURVEY James T. Massey, Gail S. Pe, Walt R. Simmns Natinal Center fr Health Statistics. INTRODUCTION In April 97, the

More information

Human papillomavirus (HPV) refers to a group of more than 150 related viruses.

Human papillomavirus (HPV) refers to a group of more than 150 related viruses. HUMAN PAPILLOMAVIRUS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between

More information

Tick fever is a cattle disease caused by any one of the following blood parasites:

Tick fever is a cattle disease caused by any one of the following blood parasites: Tick fever Tick fever is a cattle disease caused by any ne f the fllwing bld parasites: Babesia bvis Babesia bigemina Anaplasma marginale These parasites are all transmitted by the cattle tick (Bphilus

More information

Further Studies on the Influence of Steroids on

Further Studies on the Influence of Steroids on INFECTION AND IMMUNITY, Aug. 1973, p. 151-155 Cpyright ( 1973 American Sciety fr Micrbilgy Vl. 8, N. 2 Printed in U.S.A. Further Studies n the Influence f Sterids n Viral Infectin in Mice D. J. GIRON,

More information

(From the Laboratories of the International Health Division of The Rockefeller Foundation, New York)

(From the Laboratories of the International Health Division of The Rockefeller Foundation, New York) THE QUANTITATIVE DETERMINATION OF INFLUENZA VIRUS AND ANTIBODIES BY MEANS OF RED CELL AGGLUTINATION BY GEORGE K. HLRST, M.D. (Frm the Labratries f the Internatinal Health Divisin f The Rckefeller Fundatin,

More information

Vaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE

Vaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE Vaccine Infrmatin Statement: PNEUMOCOCCAL CONJUGATE VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están

More information

CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION

CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,

More information

DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS

DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 216 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS This briefing has been specifically prepared fr the Ministry f Health t prvide infrmatin frm this

More information

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...

More information

Swindon Joint Strategic Needs Assessment Bulletin

Swindon Joint Strategic Needs Assessment Bulletin Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical

More information

Q 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?

Q 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder? updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health

More information

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018) Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages

More information

TREATMENT OF POLYCYTHEMIA VERA

TREATMENT OF POLYCYTHEMIA VERA RUSSELL L. HADEN, M.D. Plycythemia vera is characterized by an increase in the number f red bld cells. This disease is insidius in rigin, chrnic, and withut pathgnmnic symptms r physical findings. Early

More information

M.J. Guthriel, D.G. Wagner2

M.J. Guthriel, D.G. Wagner2 EFFECT OF SUPPLEMENTAL PROTEIN OR GRAIN ON INTAKE AND UTILIZATION OF MEDIUM QUALITY PRAIRIE HAY BY STEERS M.J. Guthriel, D.G. Wagner2 and D.C. Weakley3 Stry in Brief Sixteen 1,053 lb tw-year-ld Herefrd

More information

Completing the NPA online Patient Safety Incident Report form: 2016

Completing the NPA online Patient Safety Incident Report form: 2016 Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject

More information

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic

More information

Pain relief after surgery

Pain relief after surgery Pain relief after surgery Imprtant infrmatin fr patients www.mchft.nhs.uk We care because yu matter This leaflet is designed t help yu cntrl any pain yu may have at hme fllwing yur peratin. Please read

More information

You may have a higher risk of bleeding if you take warfarin sodium tablets and:

You may have a higher risk of bleeding if you take warfarin sodium tablets and: MEDICATION GUIDE Warfarin (WAR-far-in) Sdium (SO-dee-um) Tablets USP The 7.5 mg tablets cntain FD&C Yellw N. 5 (tartrazine), which may cause allergic-type reactins (including brnchial asthma) in certain

More information

MEDICATION GUIDE Pioglitazone and Metformin Hydrochloride (PYE o GLI ta zone and met FOR min HYE-droe- KLOR-ide)Tablets, USP

MEDICATION GUIDE Pioglitazone and Metformin Hydrochloride (PYE o GLI ta zone and met FOR min HYE-droe- KLOR-ide)Tablets, USP MEDICATION GUIDE Piglitazne and Metfrmin Hydrchlride (PYE GLI ta zne and met FOR min HYE-dre- KLOR-ide)Tablets, USP Read this Medicatin Guide carefully befre yu start taking piglitazne and metfrmin hydrchlride

More information

Medication Guide MORPHINE SULFATE (mor-pheen) Oral Solution (CII)

Medication Guide MORPHINE SULFATE (mor-pheen) Oral Solution (CII) Medicatin Guide MORPHINE SULFATE (mr-pheen) Oral Slutin (CII) IMPORTANT: Keep Mrphine Sulfate Oral Slutin in a safe place away frm children. Accidental use by a child is a medical emergency and can cause

More information

SECTION O. MEDICATIONS

SECTION O. MEDICATIONS SECTION O. MEDICATIONS 1. NUMBER OF MEDICA TIONS (Recrd the number f different medicatins used in the last 7 days; enter "0" if nne used) O1. Number f Medicatins (7-day lk back) Intent: Prcess: Cding:

More information

Package leaflet: Information for the user. Dacepton 5 mg/ml Solution for infusion Apomorphine hydrochloride hemihydrate

Package leaflet: Information for the user. Dacepton 5 mg/ml Solution for infusion Apomorphine hydrochloride hemihydrate Package leaflet: Infrmatin fr the user Daceptn 5 mg/ml Slutin fr infusin Apmrphine hydrchlride hemihydrate Read all f this leaflet carefully befre yu start using this medicine because it cntains imprtant

More information

MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injection for intravenous infusion

MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injection for intravenous infusion MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injectin fr intravenus infusin Read this Medicatin Guide befre yu start receiving LEMTRADA and befre yu begin each treatment curse. There may be new

More information

METHYL TESTOSTERONE IN PREMATURE INFANTS

METHYL TESTOSTERONE IN PREMATURE INFANTS METHYL TESTOSTERONE IN PREMATURE INFANTS BY URSULA JAMES and B. L. COLES Frm the General Lying-In and Annie McCall Hspitals, Lndn (RECE:IVED FOR PUBLICATiN crber 18. 195 1) It is an established fact that

More information

BRCA1 and BRCA2 Mutations

BRCA1 and BRCA2 Mutations BRCA1 and BRCA2 Mutatins ROBERT LEVITT, MD JESSICA BERGER-WEISS, MD ADRIENNE POTTS, MD HARTAJ POWELL, MD, MPH COURTNEY LEVENSON, MD LAUREN BURNS, MSN, RN, WHNP OBGYNCWC.COM v Cancer is a cmplex disease

More information

Glaucoma Interviews: Due Tuesday, May 22 nd

Glaucoma Interviews: Due Tuesday, May 22 nd Glaucma Interviews: Due Tuesday, May 22 nd 1) Read the glaucma article well! It will explain what it is, plus tell yu sme symptms and risk factrs. Yu may want t use a highlighter r pen t mark imprtant

More information

MEDICATION GUIDE Pioglitazone (pie-oh-glit-ah-zohn) and Metformin (met-fore-min) Hydrochloride Tablets USP

MEDICATION GUIDE Pioglitazone (pie-oh-glit-ah-zohn) and Metformin (met-fore-min) Hydrochloride Tablets USP MEDICATION GUIDE Piglitazne (pie-h-glit-ah-zhn) and Metfrmin (met-fore-min) Hydrchlride Tablets USP Read this Medicatin Guide carefully befre yu start taking piglitazne and metfrmin hydrchlride tablets

More information

MEDICATION GUIDE. (canagliflozin) Tablets

MEDICATION GUIDE. (canagliflozin) Tablets MEDICATION GUIDE INVOKANA (in-v-kahn-uh) (canagliflzin) Tablets What is the mst imprtant infrmatin I shuld knw abut INVOKANA? INVOKANA can cause imprtant side effects, including: Dehydratin. INVOKANA can

More information

LYME DISEASE (taken from 6/20/13)

LYME DISEASE (taken from   6/20/13) LYME DISEASE (taken frm www.lymemd.rg 6/20/13) PREVENTING LYME DISEASE Understand the risks The risk f Lyme disease is year rund. Highest risk late spring t early summer. Learn t enjy the utdrs SAFELY.

More information

Assessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams

Assessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams Assessment Field Activity Cllabrative Assessment, Planning, and Supprt: Safety and Risk in Teams OBSERVATION Identify a case fr which a team meeting t discuss safety and/r safety planning is needed r scheduled.

More information

Risk factors in health and disease

Risk factors in health and disease Risk factrs in health and disease Index 1 Intrductin 2 Types f risk factrs 2.1 Behaviural risk factrs 2.2 Psychlgical risk factrs 2.3 Demgraphic risk factrs 2.4 Envirnmental risk factrs 2.5 Genetic risk

More information

MEDICATION GUIDE. (Interferon alfa-2b)

MEDICATION GUIDE. (Interferon alfa-2b) MEDICATION GUIDE INTRON A (In-trn-aye) (Interfern alfa-2b) Read this Medicatin Guide befre yu start taking INTRON A, and each time yu get a refill. There may be new infrmatin. This infrmatin des nt take

More information

H1N1 Influenza 09 Guidance for Residential Aged Care

H1N1 Influenza 09 Guidance for Residential Aged Care H1N1 Influenza 09 Guidance fr Residential Aged Care 11 June 2009 As knwledge abut H1N1 Influenza 09 develps, further advice will be prvided. Please check www.healthemergency.gv.au fr the latest infrmatin.

More information

Methadone Maintenance Treatment for Opioid Dependence

Methadone Maintenance Treatment for Opioid Dependence POLICY STATEMENT Methadne Maintenance Treatment fr Opiid Dependence APPROVED BY COUNCIL: May 2010 PUBLICATION DATE: Dialgue, Issue 2, 2010 Disclaimer: As f May 19, 2018 physicians n lnger require an exemptin

More information

CDC Influenza Division Key Points MMWR Updates February 20, 2014

CDC Influenza Division Key Points MMWR Updates February 20, 2014 CDC Influenza Divisin Key Pints MMWR Updates In this dcument: Summary Key Messages Seasnal Influenza Vaccine Effectiveness: Interim Adjusted Estimates Influenza Surveillance Update: September 29, 2013-February

More information

AP Biology Lab 12: Introduction to the Scientific Method and Animal Behavior

AP Biology Lab 12: Introduction to the Scientific Method and Animal Behavior Name: AP Bilgy Lab 12: Intrductin t the Scientific Methd and Animal Behavir Overview In this lab yu will: -Observe an rganism and design an experiment t investigate their respnses t envirnmental variables.

More information

Cnsideratin fr Optimizatin: Optimizatin is a prgram transfrmatin technique, which tries t imprve the cde by making it cnsume fewer resurces (i.e. CPU, Memry) and deliver high speed. In ptimizatin, high-level

More information

Public consultation on the NHMRC s draft revised Australian alcohol guidelines for low-risk drinking

Public consultation on the NHMRC s draft revised Australian alcohol guidelines for low-risk drinking Public cnsultatin n the NHMRC s draft revised Australian alchl guidelines fr lw-risk drinking Recmmendatins frm The Cancer Cuncil Australia The Cancer Cuncil Australia is Australia s peak nn-gvernment

More information

ALLERGY. The effect of alternate-day prednisone on the white blood count in children with chronic asthma

ALLERGY. The effect of alternate-day prednisone on the white blood count in children with chronic asthma The Jurnal f ALLERGY and CLINICAL IMMUNOLOGY VOLUME 51 NUMBER 2 The effect f alternate-day prednisne n the white bld cunt in children with chrnic asthma H. Cha, M.D., and A. Gilbert, M.T. Denver, Cl. Children

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is

More information

PATIENT INFORMATION. (methotrexate) injection, for subcutaneous use

PATIENT INFORMATION. (methotrexate) injection, for subcutaneous use What is Rasuv? PATIENT INFORMATION RASUVO (ruh-soo-vh) (methtrexate) injectin, fr subcutaneus use Rasuv is a single-dse manually-triggered aut-injectr cntaining a prescriptin medicine, methtrexate. Methtrexate

More information

CDC Influenza Division Key Points November 7, 2014

CDC Influenza Division Key Points November 7, 2014 In this dcument: Summary Key Messages FluView Activity Update LAIV Effectiveness and Vaccinatin f Children H3N2 Match and Vaccinatin Vaccine Supply Summary Key Messages This week s FluView reprt indicates

More information

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health

More information

Frequently Asked Questions: IS RT-Q-PCR Testing

Frequently Asked Questions: IS RT-Q-PCR Testing Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld

More information

Osteoporosis Fast Facts

Osteoporosis Fast Facts Osteprsis Fast Facts Fast Facts n Osteprsis Definitin Osteprsis, r prus bne, is a disease characterized by lw bne mass and structural deteriratin f bne tissue, leading t bne fragility and an increased

More information

Safety of HPV vaccination: A FIGO STATEMENT

Safety of HPV vaccination: A FIGO STATEMENT FIGO Statement n HPV Vaccinatin Safety, August 2nd, 2013 Safety f HPV vaccinatin: A FIGO STATEMENT July, 2013 Human papillmavirus vaccines are used in many cuntries; glbally, mre than 175 millin dses have

More information

Vaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE

Vaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE Vaccine Infrmatin Statement: LIVE INTRANASAL INFLUENZA VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están

More information

EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS

EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS 1 SECTION 1 INTRODUCTION: EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS The Nature Of Assessment The Definitin Of Assessment The Difference Between Testing, Measurement And Evaluatin Characteristics

More information

Adult Preventive Care Guidelines

Adult Preventive Care Guidelines Adult Preventive Care Guidelines Gundersen is yur partner fr better health. We want t wrk with yu t make sure that yu and yur family are as healthy as pssible. That can be accmplished best if we wrk tgether

More information

M.R.C.Path. causes to the raised plasma urea in patients admitted

M.R.C.Path. causes to the raised plasma urea in patients admitted Pstgradcuate Medical Jurnal (January 1979) 55, 1-14 The cause f the raised plasma urea f acute heart failure R D THOMAS MRCP D B MORGAN MRCPath ALISON NWILL AIMLS Departments f Cardilgy and Chemical Pathlgy,

More information

Medical Student Immunization Requirements

Medical Student Immunization Requirements Medical Student Immunizatin Requirements The State f Illinis cde, Reference: (110 ILCS 20) Cllege Student Immunizatin Act, requires students t prvide prf f immunity: Measles (Rubela), Mumps, Rubella (German

More information

ESCHERICHIA COLI O157:H7

ESCHERICHIA COLI O157:H7 Fact Sheet N 125 July 1996 ESCHERICHIA COLI O157:H7 1. What is Escherichia cli O157:H7? Escherichia cli is a bacterium that is a cmmn inhabitant f the gut f warm blded animals, including man. Mst strains

More information

RoActemra (tocilizumab) for Giant Cell Arteritis (GCA) subcutaneous (SC) formulation

RoActemra (tocilizumab) for Giant Cell Arteritis (GCA) subcutaneous (SC) formulation RActemra (tcilizumab) fr Giant Cell Arteritis (GCA) subcutaneus (SC) frmulatin What yu shuld knw abut RActemra This brchure prvides key infrmatin t assist in the patient s understanding f the benefits

More information

MEDICATION GUIDE. (fingolimod) capsules

MEDICATION GUIDE. (fingolimod) capsules MEDICATION GUIDE GILENYA (je-len-yah) (finglimd) capsules Read this Medicatin Guide befre yu start using GILENYA and each time yu get a refill. There may be new infrmatin. This infrmatin des nt take the

More information

Chapter 6: Impact Indicators

Chapter 6: Impact Indicators Overview Chapter 6: Impact Indicatrs The best measure f the lng-term impact f all HIV preventin activities is the HIV incidence rate, namely the number f new cases f HIV infectin per year divided by the

More information

Key Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.

Key Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red. Key Pints Entervirus D68 in the United States, 2014 Nte: Newly added infrmatin is in red. Over the last several mnths, the United States has experienced a natinwide utbreak f entervirus D68 (EV- D68) assciated

More information

A Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.

A Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol. SAMPLE INFORMED CONSENT A Phase I Study f CEP-701 in Patients with Refractry Neurblastma NANT (01-03) A New Appraches t Neurblastma Therapy (NANT) treatment prtcl. The wrd yu used thrughut this dcument

More information

Appendix C Guidelines for treating status epilepticus in adults and children

Appendix C Guidelines for treating status epilepticus in adults and children Appendix C Guidelines fr treating status epilepticus in adults and children 1.1 Treating cnvulsive status epilepticus in adults General measures 1st stage (0 10 minutes) Secure airway and resuscitate Administer

More information

Annex III. Amendments to relevant sections of the Product Information

Annex III. Amendments to relevant sections of the Product Information Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t

More information

Ruminal Availability of Phosphorus and Its Effect on Digestion

Ruminal Availability of Phosphorus and Its Effect on Digestion Table 2. Trial results Cncentratin f Captan,ppm liem 0 160 320 640 Dry matter digestibility (%) Ruminal 65.1 72.8 69.4 74.3 Ttal 82.1 81.9 82.4 82.0 Starch digestin (%) Ruminal 87.7 93.6 89.3 92.2 N digestibility

More information

Medication Guide SIGNIFOR [sig-na-for] (pasireotide) Injection

Medication Guide SIGNIFOR [sig-na-for] (pasireotide) Injection Medicatin Guide SIGNIFOR [sig-na-fr] (pasiretide) Injectin Read this Medicatin Guide befre yu start using SIGNIFOR and each time yu get a refill. There may be new infrmatin. This infrmatin des nt take

More information

How to become an AME Online

How to become an AME Online Hw t becme an AME Online 1. Check that yu meet the minimum technical requirements in rder t use the AME Online system: Operating System: Windws Vista (Service Pack 2) Windws 7 Windws 8, 8.1 Windws 10 Please

More information

A pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps.

A pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps. NAU Mdel Observatin Prtcl The mdel prtcl was develped with supprt and expertise frm the Natinal Institute fr Excellence in Teaching (NIET) and is based in great part n NIET s extensive experience cnducting

More information

Influenza (Flu) Fact Sheet

Influenza (Flu) Fact Sheet Influenza (Flu) Fact Sheet What is the flu? The flu is a cntagius respiratry illness caused by influenza viruses. It can cause mild t severe illness, and at times can lead t death. Sme peple, such as lder

More information

Before Your Visit: Mohs Skin Cancer Surgery

Before Your Visit: Mohs Skin Cancer Surgery Befre Yur Visit: Mhs Skin Cancer Surgery Yur Kaiser Permanente Care Instructins Skin Cancer Infrmatin What is skin cancer? Skin cancers are tumrs, r malignancies, f the skin. Skin cancer is assciated with

More information

potassium status of patients with heart failure

potassium status of patients with heart failure Pstgraduate Medical Jurnal (June 1978) 54, 45-49. The effects f ptassium supplements, spirnlactne r amilride n the ptassium status f patients with heart failure C. DAVIDSON M.A., M.B., M.R.C.P. D. B. MORGAN

More information

Interpretation. Historical enquiry religious diversity

Interpretation. Historical enquiry religious diversity Name: Year 8 Histry Prject 3: D The Cmmnwealth Games Still Matter In The 21 st Century? Mdule: Date Set: Deadline: Descriptin f the task: The prject is split int three separate parts: The prject is split

More information

The principles of evidence-based medicine

The principles of evidence-based medicine The principles f evidence-based medicine By the end f this mdule yu shuld be able t: Describe what evidence based medicine is Knw where t find quality evidenced based medicine n the internet Be able t

More information

PET FORM Planning and Evaluation Tracking ( Assessment Period)

PET FORM Planning and Evaluation Tracking ( Assessment Period) Divisin f: Behaviral Studies PET FORM Planning and Evaluatin Tracking (2010 2011 Assessment Perid) Persn Respnsible fr this Divisin: Jerry Mller Department f: Behaviral Sciences Persn Respnsible fr this

More information

Immunisation and Disease Prevention Policy

Immunisation and Disease Prevention Policy Immunisatin and Disease Preventin Plicy Quality Area 2: Children s Health and Safety 2.1 Each child s health is prmted 2.1.4 Steps are taken t cntrl the spread f infectius diseases and t manage injuries

More information

Key Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.

Key Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red. Key Pints Entervirus D68 in the United States, 2014 Nte: Newly added infrmatin is in red. The United States is currently experiencing a natinwide utbreak f entervirus D68 (EV-D68) assciated with severe

More information

Pediatric and adolescent preventive care and HEDIS *

Pediatric and adolescent preventive care and HEDIS * Pediatric and adlescent preventive care and HEDIS * * HEDIS is a registered trademark f the Natinal Cmmittee fr Quality Assurance (NCQA). UniCare Health Plan f West Virginia, Inc. Healthcare Effectiveness

More information

Imaging tests allow the cancer care team to check for cancer and other problems inside the body.

Imaging tests allow the cancer care team to check for cancer and other problems inside the body. IMAGING TESTS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between yu

More information

FOUNDATIONS OF DECISION-MAKING...

FOUNDATIONS OF DECISION-MAKING... Table f Cntents FOUNDATIONS OF DECISION-MAKING... Errr! Bkmark nt Describe the decisin-making prcess pp.62-66... Errr! Bkmark nt Explain the three appraches managers can use t make decisins pp.67-70 Errr!

More information

Percutaneous Nephrolithotomy (PCNL)

Percutaneous Nephrolithotomy (PCNL) Percutaneus Nephrlithtmy (PCNL) What is a percutaneus nephrlithtmy? is the mst effective f the cmmnly perfrmed prcedures fr kidney stnes. It is the best prcedure fr large and cmplex stnes. T perfrm this

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial infrmatin prvided in this public disclsure synpsis is supplied fr infrmatinal purpses nly. Please nte that the results reprted in any single trial may nt reflect the verall ptential

More information

FDA Dietary Supplement cgmp

FDA Dietary Supplement cgmp FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes

More information

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion Intravenus Vancmycin Use in Adults Intermittent (Pulsed) Infusin Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment

More information

Refining Blood Collection Techniques to Improve Animal Welfare and Sample Quality

Refining Blood Collection Techniques to Improve Animal Welfare and Sample Quality Refining Bld Cllectin Techniques t Imprve Animal Welfare and Sample Quality Amy Allaire RLATG 1, Jennifer Jhnsn 2, Kimberly Maratea DVM PhD 2, Steven Bulé CMAR RLATG 1, Sara Savage DVM DACLAM 1 1 Dispsitin,

More information

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER (Sanfi-Aventis France), NT001 Suppliers submissin f the SRA apprved text Octber 2016 Name f the medicinal prduct Text bx PACKAGE LEAFLET: INFORMATION FOR THE USER NOTEZINE 100 mg, scred tablets Diethylcarbamazine

More information

PART III: CONSUMER INFORMATION

PART III: CONSUMER INFORMATION IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION Pr ZERIT Stavudine This leaflet is Part III f a three-part Prduct Mngaph published when ZERIT was apprved fr sale in Canada and is designed specifically

More information

Tendon problems can happen in people of all ages who take levofloxacin. Tendons are tough cords of tissue that connect muscles to bones.

Tendon problems can happen in people of all ages who take levofloxacin. Tendons are tough cords of tissue that connect muscles to bones. Medicatin Guide LEVOFLOXACIN (LEE ve FLOX a sin) INJECTION, 25 mg/ml and LEVOFLOXACIN (LEE ve FLOX a sin) INJECTION in 5% Dextrse fr Intravenus Use Read this Medicatin Guide befre yu start taking levflxacin

More information

BLOOD BORNE PATHOGENS

BLOOD BORNE PATHOGENS BLOOD BORNE PATHOGENS GALVESTON ISD ANNUAL TRAINING 2018-2019 Galvestn Independent Schl District Special Prgrams/ECH Health Services Required Training Ò Training is required by the Texas Department f Health

More information

454-8 (Insert) MEDICATION GUIDE ZUBSOLV (Zub-solve) (buprenorphine and naloxone) Sublingual Tablet (CIII) IMPORTANT: Keep ZUBSOLV in a secure place

454-8 (Insert) MEDICATION GUIDE ZUBSOLV (Zub-solve) (buprenorphine and naloxone) Sublingual Tablet (CIII) IMPORTANT: Keep ZUBSOLV in a secure place MEDICATION GUIDE ZUBSOLV (Zub-slve) (buprenrphine and nalxne) Sublingual Tablet (CIII) IMPORTANT: Keep ZUBSOLV in a secure place away frm children. Accidental use by a child is a medical emergency and

More information

LTCH QUALITY REPORTING PROGRAM

LTCH QUALITY REPORTING PROGRAM 4 LTCH QUALITY REPORTING PROGRAM GENERAL INFORMATION...3 LTCH FACILITY-LEVEL QUALITY MEASURE REPORT...5 LTCH PATIENT-LEVEL QUALITY MEASURE REPORT...18 LTCH REVIEW AND CORRECT REPORT...23 09/2018 v1.04

More information

Record of Revisions to Patient Tracking Spreadsheet Template

Record of Revisions to Patient Tracking Spreadsheet Template Recrd f Revisins t Patient Tracking Spreadsheet Template Belw is a recrd f revisins made by the AIMS Center t the Patient Tracking Spreadsheet Template. The purpse f this dcument is t infrm spreadsheet

More information

Sugar Rush: The Science of Sweet

Sugar Rush: The Science of Sweet Sugar Rush: The Science f Sweet FRAMEWORK I. Scientific and Engineering Practices II. Crss-Cutting Cncepts III. Physical Sciences SKILLS/OBJECTIVES T bserve the results f hands-n experiments and make inferences/draw

More information

Taste-sickness associations in youngrats over varying delays, stimulus, and test conditions

Taste-sickness associations in youngrats over varying delays, stimulus, and test conditions Animal Learning & Behavir 1980, 8(4), 529-533 Taste-sickness assciatins in yungrats ver varying delays, stimulus, and test cnditins GERARD M. MARTIN and W. K. TIMMINS Australian Natinal University, Canberra,

More information

CONSENT FORM - TESTOSTERONE FOR TRANSGENDER CLIENTS

CONSENT FORM - TESTOSTERONE FOR TRANSGENDER CLIENTS CONSENT FORM - TESTOSTERONE FOR TRANSGENDER CLIENTS Yu want t take teststerne t masculinize yur bdy. Befre taking it, there are several things yu need t knw abut. They are the pssible advantages, disadvantages,

More information

LATENT VIRAL INFECTION OF CELLS IN TISSUE CULTURE BY JOHN P. BADER, PH.D., AND HERBERT R. MORGAN, M.D.

LATENT VIRAL INFECTION OF CELLS IN TISSUE CULTURE BY JOHN P. BADER, PH.D., AND HERBERT R. MORGAN, M.D. Published Online: 1 February, 1961 Supp Inf: http://di.rg/1.184/jem.113.2.271 Dwnladed frm jem.rupress.rg n August 22, 218 LATENT VIRAL INFECTION OF CELLS IN TISSUE CULTURE VII. ROLE OF V~ATER-SOLUBLE

More information

TABLE OF CONTENTS Glossary of terms Code Pad Diagram 3. Understanding the Code Pad lights.4.

TABLE OF CONTENTS Glossary of terms Code Pad Diagram 3. Understanding the Code Pad lights.4. TABLE OF CONTENTS... Glssary f terms 2... Cde Pad Diagram 3 Understanding the Cde Pad lights.4 Cde Pad tnes 5 Fully arming the system - ON MODE 6 Fully arming the system - Quick Arm MODE 6 Partially arming

More information

Name of procedure: Removal of submandibular salivary gland

Name of procedure: Removal of submandibular salivary gland Oral facial surgery Surgical prcedure infrmatin leaflet Name f prcedure: Remval f submandibular salivary gland This leaflet explains sme f the benefits, risks and alternatives t the peratin. We want yu

More information

Package leaflet: Information for the user. Fragmin Graduated Syringe 10,000 IU/ml Solution for Injection dalteparin sodium

Package leaflet: Information for the user. Fragmin Graduated Syringe 10,000 IU/ml Solution for Injection dalteparin sodium Package leaflet: Infrmatin fr the user Fragmin Graduated Syringe 10,000 IU/ml Slutin fr Injectin dalteparin sdium Read all f this leaflet carefully befre yu start using this medicine because it cntains

More information

SCALES NW HEARING PROTECTION PROGRAM

SCALES NW HEARING PROTECTION PROGRAM PURPOSE Expsure t excessive nise in the wrkplace can cause permanent hearing lss. The Hearing Prtectin Prgram has been established t help ensure that emplyees f Scales NW, Inc. d nt suffer health effects

More information

DIRECTED FORGETIING: SHORT-TERM MEMORY OR CONDITIONED RESPONSE? WENDY S. MILLER and HARVARD L. ARMUS The University of Toledo

DIRECTED FORGETIING: SHORT-TERM MEMORY OR CONDITIONED RESPONSE? WENDY S. MILLER and HARVARD L. ARMUS The University of Toledo The Psychlgical Recrd, 1999, 49, 211-220 DIRECTED FORGETIING: SHORT-TERM MEMORY OR CONDITIONED RESPONSE? WENDY S. MILLER and HARVARD L. ARMUS The University f Tled Previus researchers have interpreted

More information

Year 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher:

Year 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher: Year 10 Fd Technlgy Assessment Task 1: Fds fr Special Needs Name: Teacher: Due Date: Term 2, Week 1 Type f Task: Design Task Planning Fd Requirements Cllectin f Assessment: Submit in Class Assessment Plicy:

More information

In the last lesson we examined specific factors that affect ecosystems.

In the last lesson we examined specific factors that affect ecosystems. Lessn 3: Liming Factrs in Ecsystems In the last lessn we examined specific factrs that affect ecsystems. In this lessn, yu will see hw these and ther factrs limit ppulans and cmmunies within ecsystems. Bitic

More information

ALCAT FREQUENTLY ASKED QUESTIONS

ALCAT FREQUENTLY ASKED QUESTIONS 1. Is fasting required befre taking the Alcat Test? N. It is recmmended t drink water and t avid stimulants like caffeine prir t the test. 2. With regard t testing children, must a child be a certain age

More information